Sino Biopharmaceutical Limited

As of December 31, 2021, Sino Biopharmaceutical Limited carries a market capitalization of 102.86B, placing it among publicly traded companies globally. Its enterprise value stands at 107.48B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sino Biopharmaceutical Limited's next confirmed earnings release is scheduled for April 1, 2027.

As of December 31, 2021, Sino Biopharmaceutical Limited has 18.84B shares outstanding.

These figures are as of December 31, 2021.

As of December 31, 2021, Sino Biopharmaceutical Limited maintains a current ratio of 1.53, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2021.

Over the twelve months ended December 31, 2021, Sino Biopharmaceutical Limited recorded 1.51B in income tax expense.

As of the close on October 22, 2026, Sino Biopharmaceutical Limited's stock has declined approximately 30.83% over the past 52 weeks. The 50-day moving average sits at 5.42, while the 200-day moving average is 5.61.

As of December 31, 2021, Sino Biopharmaceutical Limited holds 19.38B in cash and equivalents against 14.87B in total debt, resulting in a net debt position of 1.43B. Total book value stands at 37.18B, with working capital of 10.01B providing operational flexibility.

Sino Biopharmaceutical Limited's most recent stock split took place on July 20, 2020 with a 2:3 split ratio.